First Trust Advisors LP grew its holdings in Qiagen NV (NYSE:QGEN) by 6.8% in the 1st quarter, HoldingsChannel reports. The fund owned 2,685,140 shares of the company’s stock after buying an additional 169,926 shares during the period. First Trust Advisors LP’s holdings in Qiagen were worth $109,231,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of QGEN. Lindbrook Capital LLC acquired a new stake in Qiagen in the fourth quarter worth about $25,000. Captrust Financial Advisors boosted its holdings in Qiagen by 165.3% in the fourth quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock worth $35,000 after acquiring an additional 628 shares in the last quarter. Cornerstone Advisors Inc. acquired a new stake in Qiagen in the first quarter worth about $44,000. Bremer Trust National Association acquired a new stake in Qiagen in the fourth quarter worth about $45,000. Finally, Truvestments Capital LLC acquired a new stake in Qiagen in the first quarter worth about $67,000. 65.12% of the stock is owned by institutional investors and hedge funds.
Qiagen stock opened at $38.20 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.69 and a quick ratio of 1.52. Qiagen NV has a 52 week low of $32.33 and a 52 week high of $41.55. The stock has a market cap of $8.61 billion, a P/E ratio of 28.51, a PEG ratio of 2.31 and a beta of 0.88.
Qiagen (NYSE:QGEN) last released its earnings results on Monday, May 6th. The company reported $0.27 EPS for the quarter, topping the Zacks’ consensus estimate of $0.26 by $0.01. The firm had revenue of $348.70 million during the quarter, compared to the consensus estimate of $351.68 million. Qiagen had a return on equity of 12.22% and a net margin of 12.45%. The company’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 earnings per share. On average, equities analysts anticipate that Qiagen NV will post 1.43 EPS for the current fiscal year.
Several equities research analysts have weighed in on the company. Zacks Investment Research downgraded Qiagen from a “hold” rating to a “sell” rating in a report on Monday, April 15th. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a report on Friday, April 12th. Goldman Sachs Group reaffirmed a “buy” rating on shares of Qiagen in a report on Tuesday, May 7th. Finally, UBS Group began coverage on Qiagen in a report on Friday, March 15th. They set a “neutral” rating and a $42.00 target price for the company. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $41.71.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Recommended Story: How Do Front-End Loads Impact an Investment?
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.